Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Filing for Approval of Avastin Biosimilar is Accepted in China

publication date: Jan 30, 2019

Suzhou's Innovent Biologics reported that the NMPA accepted the company's filing of an NDA for its biosimilar to bevacizumab (Avastin). After scoring approvals for two drugs in late 2018 -- Tyvyt, a PD-1 drug, and IBI-303, a biosimilar to arthritis treatment Humira -- the company has announced three China acceptances of NDA filings in a month. The Avastin biosimilar acceptance is based on clinical data from two clinical studies comparing IBI-305 to the reference drug. Innovent develops novel drugs for oncology, autoimmune and other diseases. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.